FLIR Systems Announces Artificial Intelligence Traffic Cameras for Predictive Traffic Management
9.11.2020 16:00:00 EET | Business Wire | Press release
FLIR Systems, Inc. today announced two intelligent traffic system cameras, the FLIR ThermiCam™ AI* with thermal imaging and the FLIR TrafiCam™ AI visible camera, both with artificial intelligence (AI) to optimize traffic flow on roadways and at intersections. When combined with the FLIR Acyclica™ cloud platform, cities can apply the AI-camera data to predict traffic, prevent congestion and potential accidents, and create safer roads for drivers, cyclists, and pedestrians 24 hours a day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005113/en/
Traffic engineers apply data from AI-enabled cameras, FLIR ThermiCam AI and TrafiCam AI, to predict traffic and prevent congestion and potential accidents for safer roads. (Photo: Business Wire)
“FLIR traffic systems are currently installed in 75 countries, and with the addition of ThermiCam AI and TrafiCam AI, FLIR now offers a fully integrated solution that enables traffic engineers and city planners to apply AI-based learnings to continuously optimize traffic flow,” said Rickard Lindvall, General Manager, Solutions Business, FLIR Systems. “The integrated solution enables cities to improve urban roadway design to make cities safer and more livable.”
The AI-enabled cameras help control traffic dynamically at the edge through real-time data capture and processing, and provide input to traffic signal controllers at intersections, which improves traffic flow and safety in the moment. With the ability to capture heat energy data through a thermal sensor within the ThermiCam AI, and a visible low-light, high-definition sensor within the TrafiCam AI, cities’ traffic signals have complete continuous monitoring, in all weather conditions and even through smoke for tunnel monitoring. The cameras are also Wi-Fi enabled for travel time calculations and other origin-destination applications. In the future, the cameras can be retrofitted with 5G cellular antennas to support vehicle-to-everything (V2X) connectivity, which will further improve road safety.
The FLIR Acyclica cloud platform provides the tools and analytics needed to better understand traffic data. When ThermiCam AI and TrafiCam AI are paired with the Acyclica cloud platform, cities can apply their AI-based learnings to real time data to make predictive traffic pattern changes for more efficient and safer cities.
The new AI traffic cameras are available globally in the first quarter of 2021. To learn more about FLIR ThermiCam AI and TrafiCam AI, visit www.flir.com/thermicam-ai and www.flir.com/traficam-ai. For more information about FLIR traffic solutions, visit www.flir.com/traffic/.
*The ThermiCam AI camera is sold as the TrafiSense ™ AI camera in the United States and Canada. To learn more visit www.flir.com/trafisense-ai.
About FLIR Systems, Inc .
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense and industrial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense, creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005113/en/
Contact information
Media Relations:
Eleana Stayer
Phone: +44 7545 204375
Email: eleana.stayer@flir.com
Investor Relations:
Lasse Glassen
Addo Investor Relations
Phone: 424-238-6249
Email: lglassen@addoir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Techtronic Industries Delivers Strong First Half Performance4.8.2026 14:20:00 EEST | Press release
Techtronic Industries Co. Ltd. (“TTI” or the “Group”) (stock code: HK: 0669, ADR symbol: TTNDY), a global cordless power tool, outdoor power equipment and floorcare & cleaning company, is pleased to announce its results for the six-month period ended June 30, 2026. The Group delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion. Its two leading brands, MILWAUKEE and RYOBI, both delivered a strong performance in the first half of 2026, growing at a combined 8.2% underlying growth rate in local currency. TTI delivered record first half results in 2026, with revenue growing 5.9% to US$8.3 billion and net profit increasing 17.5% to US$738 million. Our global MILWAUKEE business grew 10.5% on an underlying basis in local currency, after adjusting for the planned 2025 timing impact related to the MILWAUKEE Americas ERP system conversion. RYOBI, the #1 global consumer cordless tool and outdoor products brand, grew 1.7% in local currency to US$1.9 billion in t
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 12:00:00 EEST | Press release
WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, uses biomarker data, including temperature and heart rate data, to identify fertile and non-fertile days, helping users prevent pregnancy without hormones while also providing fertility insights. Beyond birth control, the app
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 11:00:00 EEST | Press release
Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphatax's long-term vision for the future of tax technology. By bringing these transfer pric
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom